Understanding how genetic differences affect immune responses to COVID-19 vaccines
HLA class I peptidome diversities and CD8+ T cell responses to COVID-19 vaccines
This study is looking at how different types of a protein called HLA in our bodies affect how well our immune cells respond to COVID-19 vaccines, and it's for anyone interested in understanding how vaccines might work better for different people.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Michigan at Ann Arbor NIH-funded |
| Lab location | 1 site (Ann Arbor, United States) |
| Project ID | NIH-10632096 on NIH RePORTER |
What this research studies
This research investigates how variations in human leukocyte antigens (HLA) influence the immune response of CD8+ T cells to COVID-19 vaccines. By analyzing blood samples from vaccinated individuals with different HLA types, the study aims to identify the specific peptide sequences that trigger immune activation. Using advanced mass spectrometry techniques, researchers will measure the diversity of peptide binding and its impact on the effectiveness of the vaccine. This could help tailor vaccine strategies to improve immune responses in different populations.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals who have been vaccinated against COVID-19 and have undergone HLA genotyping.
Not a fit: Patients who have not been vaccinated against COVID-19 or do not have available HLA genotype data may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective COVID-19 vaccination strategies tailored to individual genetic profiles.
How similar studies have performed: Previous research has shown that understanding HLA diversity can significantly impact vaccine efficacy, suggesting this approach has potential for success.
Where this research is happening
Ann Arbor, United States
- University of Michigan at Ann Arbor — Ann Arbor, United States (Active)
Researchers
- Principal investigator: Raghavan, Malini — University of Michigan at Ann Arbor
- Study coordinator: Raghavan, Malini
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.